PRTA - NASDAQ

Prothena Corporation plc

PRTA·NASDAQ

$8.92

-2.9%

HealthcareBiotechnology

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$466.99M

EPS-4.5300

P/E Ratio-1.97

Earnings Date08/03/2026

326.80M

Assets

-40%

3Y-57.0%

5Y-2.0%

10Y-29.0%

46.33M

Total Liabilities

-23%

3Y-66.0%

5Y-69.0%

10Y-51.0%

280.47M

Total Equity

-42%

3Y-55.0%

5Y+52.0%

10Y-23.0%

Prothena Corporation plc Funding & Solvency Profile

PRTA · NASDAQ

Current Assets

Cash & Cash Equivalents307.53M

Net Receivables0.00

Inventory0.00

Other Current Assets7.66M

Total Current Assets315 M

Non-Current Assets

Property, Plant & Equipment10.27M

Goodwill & Intangible Assets0.00

Long-Term Investments860.00K

Other Non-Current Assets482.00K

Total Non-Current Assets12 M

Total Assets

326.80M

Financial Health Analysis

Current Ratio

7.72x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.17x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

274 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Prothena Corporation plc Balance Sheet

PRTA • NASDAQ

Prothena Corporation plc Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	307.5M	471.4M	618.8M	710.4M	579.1M	295.4M	375.7M	427.7M	417.6M	386.9M	370.6M	293.6M	176.7M	124.9M	0.0	0.0
Cash & Short-Term Investments	307.5M	471.4M	618.8M	710.4M	579.1M	295.4M	375.7M	427.7M	417.6M	386.9M	370.6M	293.6M	176.7M	124.9M	0.0	0.0
Net Receivables	0.0	0.0	5.2M	62K	13K	15K	68K	2K	240K	178K	509K	1.8M	58K	223K	0.0	0.0
Accounts Receivables	0.0	0.0	5.2M	0.0	13K	15K	68K	2K	240K	178K	509K	1.8M	58K	223K	0.0	0.0
Other Receivables	0.0	0.0	0.0	62K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-240K	-178K	-509K	-1.8M	-58K	-223K	0.0	0.0
Prepaids	0.0	12.9M	11.8M	6.9M	4.9M	2.5M	2.6M	3.7M	8.5M	4.3M	6.3M	3.8M	1.4M	685K	124K	0.0
Other Current Assets	7.7M	1.2M	3.5M	1.7M	766K	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	81K	73K	0.0	0.0
Total Current Assets	315.2M	485.4M	639.3M	719.1M	584.8M	299.3M	378.4M	431.4M	426.3M	391.4M	377.4M	299.3M	178.2M	125.8M	124K	0.0
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	10.3M	13.8M	16M	8M	14.1M	20.4M	27.1M	52.8M	55M	56.5M	3.9M	3.1M	3.4M	3.4M	2.5M	2.4M
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49K	70K	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4.1M	-4.1M	-4.1M	0.0	0.0	0.0	49K	70K	0.0
Long-Term Investments	860K	860K	0.0	0.0	0.0	0.0	0.0	4.1M	4.1M	4.1M	0.0	0.0	0.0	-122K	0.0	0.0
Tax Assets	0.0	43.2M	33.9M	18.2M	7.1M	11.6M	10M	9.7M	8.1M	5.9M	2.9M	1.7M	816K	73K	0.0	0.0
Other Non-Current Assets	482K	3.8M	7.2M	12.7M	3.4M	1.7M	3.8M	4.9M	6.9M	6.2M	1.1M	0.0	0.0	49K	885K	900K
Total Non-Current Assets	11.6M	61.7M	57.1M	38.9M	24.6M	33.7M	40.9M	67.4M	70M	68.6M	7.8M	4.8M	4.2M	3.4M	3.5M	3.3M
Total Assets	326.8M	547.1M	696.4M	758M	609.4M	333M	419.3M	498.8M	496.3M	460M	385.2M	304.1M	182.4M	129.3M	3.6M	3.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.9M	7.8M	25.4M	9.3M	3.7M	4.2M	1.2M	1.5M	13.6M	13.1M	4.5M	4.7M	1.8M	27K	380K	600K
Accounts Payable	5.9M	7.8M	25.4M	9.3M	3.7M	4.1M	1.2M	1.5M	13.6M	13.1M	4.5M	4.7M	1.8M	0.0	380K	100K
Other Payables	0.0	0.0	0.0	0.0	0.0	36K	5K	0.0	0.0	0.0	0.0	0.0	0.0	27K	0.0	500K
Accrued Expenses	0.0	0.0	28.3M	22.5M	15.8M	15.7M	11M	11M	21.3M	26.1M	16.9M	6.6M	5M	1.7M	7.7M	0.0
Short Term Debt	2.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	2.6M	1.1M	6.5M	5.9M	5.5M	5.1M	1.6M	733K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	36K	5K	54K	311K	378K	98K	57K	184K	27K	0.0	500K
Deferred Revenue	2.7M	8.9M	0.0	11.4M	7.7M	0.0	0.0	110.2M	-857K	363K	284K	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	29.4M	29.3M	2.1M	503K	405K	516K	322K	837K	1.7M	1.9M	804K	725K	658K	51K	288K	1.2M
Total Current Liabilities	40.8M	48.5M	56.9M	50.1M	33.5M	25.8M	17.7M	14.9M	37.4M	41.1M	22.2M	12M	7.4M	1.7M	8.4M	1.8M
NON-CURRENT LIABILITIES
Long Term Debt	5.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	3.4M	67.4M	85.3M	102.9M	110.2M	110.2M	110.2M	254K	2.1M	2.1M	0.0	0.0	0.0	0.0	1.4M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-49.9M	-254K	-2.1M	0.0	1.7M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-5.5M	0.0	0.0	553K	553K	553K	553K	111M	254K	2.2M	2.4M	468K	1.7M	1.1M	1.7M	0.0
Total Non-Current Liabilities	5.5M	11.7M	78.1M	85.8M	109.9M	123.1M	128.6M	160.9M	51.8M	53.5M	2.4M	2.2M	1.7M	1.1M	1.7M	1.4M
Capital Lease Obligations	5.5M	10.8M	11.8M	6.5M	12.3M	17.8M	22.9M	51.5M	52.2M	51.3M	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	46.3M	60.2M	135M	136M	143.3M	149M	146.3M	175.8M	89.1M	94.6M	24.6M	14.2M	9.1M	2.8M	10.1M	3.2M
SHAREHOLDERS' EQUITY
Common Stock	538K	538K	537K	521K	466K	399K	399K	399K	385K	348K	317K	274K	219K	177K	0.0	0.0
Additional Paid-In Capital	1.6B	1.6B	1.5B	1.5B	1.2B	966.6M	944.4M	920.6M	849.2M	654.3M	489.5M	338.1M	214.4M	126.7M	0.0	0.0
Retained Earnings	-1.3B	-1.1B	-980M	-833M	-716.1M	-783M	-671.9M	-598M	-442.4M	-289.2M	-129.1M	-48.5M	-41.3M	-345K	0.0	-12.5M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.5M	-7.7M	-7.7M	-5.3M	-4.7M	-4.3M	-3.7M	-568K	12.6M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.4M	0.0
Total Stockholders' Equity	280.5M	486.9M	561.4M	622M	466M	184M	272.9M	323M	407.2M	365.4M	360.7M	289.9M	173.3M	126.5M	-6.4M	100K
Total Equity	280.5M	486.9M	561.4M	622M	466M	184M	272.9M	323M	407.2M	365.4M	360.7M	289.9M	173.3M	126.5M	-6.4M	100K
SUMMARY
Total Liabilities & Equity	326.8M	547.1M	696.4M	758M	609.4M	333M	419.3M	498.8M	496.3M	460M	385.2M	304.1M	182.4M	129.3M	3.6M	3.3M
Total Investments	860K	860K	0.0	0.0	0.0	0.0	0.0	4.1M	4.1M	4.1M	0.0	0.0	0.0	-122K	0.0	0.0
Total Debt	13.9M	10.8M	11.8M	6.5M	12.3M	17.8M	22.9M	51.5M	52.2M	51.3M	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-293.7M	-460.5M	-607M	-703.9M	-566.8M	-277.5M	-352.8M	-376.1M	-365.4M	-335.6M	-370.6M	-293.6M	-176.7M	-124.9M	0.0	0.0
Shares Outstanding	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237	52,353,237

SEC Filings

PRTA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 15, 2026	May 14, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 27, 2026	May 14, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 19, 2026	February 19, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 12, 2025	December 10, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 19, 2025	November 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing

Showing 1 to 10 of 234 filings

Related Guides

Blog Categories

Continue your PRTA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.